Literature DB >> 25469287

Factors predicting survival following complete surgical remission of pulmonary metastasis in osteosarcoma.

Samer Salah1, Samar Toubasi2.   

Abstract

Pulmonary metastasectomy (PM) is associated with improved survival of patients with metastatic osteosarcoma; however, the factors affecting survival following achievement of complete surgical remission remain controversial. The main objective of this study was to report the outcomes and prognostic factors of osteosarcoma patients who achieved complete remission (CR) following PM. We analyzed the effect of demographic and disease-related characteristics on the overall survival (OS) of consecutive patients with metastatic osteosarcoma who were treated at a single institution and achieved CR following PM, through univariate and multivariate analyses. Between January, 2000 and August, 2013, 62 patients with metastatic osteosarcoma were treated and followed up at our institution. A total of 25 patients achieved CR following PM and were included in this analysis. The 5-year OS and disease-free survival following PM were 30 and 21%, respectively. The factors correlated with inferior OS in the univariate analysis included chondroblastic subtype, post-chemotherapy necrosis <90% in the primary tumor, metastasis detected during neoadjuvant or adjuvant chemotherapy and pathological identification of tumor cells reaching the visceral pleural surface of any of the resected nodules. In the multivariate analysis, the chondroblastic subtype was the sole independent adverse prognostic factor (HR=4.6, 95% CI: 1.0-21.3, P=0.044). Therefore, factors associated with tumor biology, including poor tumor necrosis in the primary tumor and detection of metastasis during primary chemotherapy, are associated with poor post-metastasectomy survival. In addition, chondroblastic subtype and visceral pleural involvement predicted poor prognosis in our series.

Entities:  

Keywords:  complete remission; osteosarcoma; overall survival; prognosis; pulmonary metastasectomy

Year:  2014        PMID: 25469287      PMCID: PMC4251136          DOI: 10.3892/mco.2014.426

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  21 in total

1.  Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy.

Authors:  Gaetano Bacci; Antonio Briccoli; Alessandra Longhi; Stefano Ferrari; Mario Mercuri; Franca Faggioli; Michela Versari; Piero Picci
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

2.  Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases.

Authors:  J F Huth; F R Eilber
Journal:  Arch Surg       Date:  1989-01

Review 3.  [Pulmonary metastasectomy for osteosarcomas and soft tissue sarcomas].

Authors:  Hideki Kimura; Makoto Suzuki; Sohichiro Ando; Tomohiko Iida; Takekazu Iwata; Sinichiro Tatesaki; Takesi Isii; Tsukasa Yonemoto
Journal:  Gan To Kagaku Ryoho       Date:  2004-09

4.  The metastasectomy and timing of pulmonary metastases on the outcome of osteosarcoma patients.

Authors:  Yu-Min Huang; Chun-Han Hou; Sheng-Mou Hou; Rong-Sen Yang
Journal:  Clin Med Oncol       Date:  2009-09-14

5.  Aggressive metastasectomy for pulmonic sarcomatous metastases: a follow-up study.

Authors:  D A Saltzman; C L Snyder; K L Ferrell; R C Thompson; A S Leonard
Journal:  Am J Surg       Date:  1993-11       Impact factor: 2.565

6.  Pulmonary resection for metastatic osteosarcomas: a retrospective analysis of 21 patients.

Authors:  J Pfannschmidt; J Klode; T Muley; H Hoffmann; H Dienemann
Journal:  Thorac Cardiovasc Surg       Date:  2006-03       Impact factor: 1.827

7.  Prognostic factors in pulmonary metastasized high-grade osteosarcoma.

Authors:  Emilie P Buddingh; Jakob K Anninga; Michel I M Versteegh; Antonie H M Taminiau; R Maarten Egeler; Catherina S P van Rijswijk; Pancras C W Hogendoorn; Arjan C Lankester; Hans Gelderblom
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

8.  Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases.

Authors:  A H Aljubran; A Griffin; M Pintilie; M Blackstein
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976

9.  Prognostic factors of pulmonary metastasectomy for osteosarcomas of the extremities.

Authors:  Fengshi Chen; Ryo Miyahara; Toru Bando; Kenichi Okubo; Kenichiro Watanabe; Tomitaka Nakayama; Junya Toguchida; Hiroshi Date
Journal:  Eur J Cardiothorac Surg       Date:  2008-08-30       Impact factor: 4.191

10.  Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.

Authors:  Hans Gelderblom; Rachel C Jinks; Matthew Sydes; Vivien H C Bramwell; Martine van Glabbeke; Robert J Grimer; Pancras C W Hogendoorn; Anne McTiernan; Ian J Lewis; Marianne A Nooij; Antonie H M Taminiau; Jeremy Whelan
Journal:  Eur J Cancer       Date:  2011-01-06       Impact factor: 9.162

View more
  7 in total

1.  Celastrol negatively regulates cell invasion and migration ability of human osteosarcoma via downregulation of the PI3K/Akt/NF-κB signaling pathway in vitro.

Authors:  Xiaolong Yu; Qiang Wang; Xin Zhou; Changlin Fu; Ming Cheng; Runsheng Guo; Hucheng Liu; Bin Zhang; Min Dai
Journal:  Oncol Lett       Date:  2016-08-26       Impact factor: 2.967

Review 2.  Pulmonary metastasectomy: an overview.

Authors:  Francesco Petrella; Cristina Diotti; Arianna Rimessi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

3.  The Functional Role of PMP22 Gene in the Proliferation and Invasion of Osteosarcoma.

Authors:  Shuyong Liu; Zhiping Chen
Journal:  Med Sci Monit       Date:  2015-07-08

4.  pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.

Authors:  Kamolrat Thanapprapasr; Adisak Nartthanarung; Duangmani Thanapprapasr; Artit Jinawath
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

5.  Risk and Prognostic Factors for Different Organ Metastasis in Primary Osteosarcoma: A Large Population-Based Analysis.

Authors:  Guijun Xu; Haixiao Wu; Yanting Zhang; Yao Xu; Xu Guo; Vladimir P Baklaushev; Vladimir P Chekhonin; Karl Peltzer; Jun Wang; Feng Lu; Guowen Wang; Xin Wang; Wenjuan Ma; Chao Zhang
Journal:  Orthop Surg       Date:  2022-03-16       Impact factor: 2.071

6.  Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.

Authors:  Dongqing Zuo; Zifei Zhou; Hongsheng Wang; Tao Zhang; Jie Zang; Fei Yin; Wei Sun; Jiepeng Chen; Lili Duan; Jing Xu; Zhuoying Wang; Chongren Wang; Binhui Lin; Zeze Fu; Yuxin Liao; Suoyuan Li; Mengxiong Sun; Yingqi Hua; Longpo Zheng; Zhengdong Cai
Journal:  J Cell Mol Med       Date:  2016-09-14       Impact factor: 5.310

7.  Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice.

Authors:  Sun Xin; Guo Wei
Journal:  J Bone Oncol       Date:  2020-02-21       Impact factor: 4.072

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.